A world leader in genomic-based diagnostic tests had developed a unique test to predict the likelihood of treatment benefit as well as the chance of recurrence for a particular type of newly diagnosed cancer.

Most patients with this cancer undergo immediate surgical treatment, and the diagnostic test helps determine if further chemotherapy treatment will be beneficial. The test had substantial clinical evidence including a very large prospective patient outcomes study which was newly released. Despite excellent patient benefit, previous utilization by some physicians had been limited.